AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9314121 — intervention group
Group type: EXPERIMENTAL
Intervention: History of trauma
Number of subjects: 1180
Study 9314121 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-HCV detection
Number of subjects: 1180
Study 9314121 — intervention group
Group type: EXPERIMENTAL
Intervention: Viraemia and genotype distribution
Number of subjects: 1180
Study 8380634 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (CDDP; 80 mg/m2 on day 1) plus Vindesine (VDS; 3 mg/m2 on days 1 and 8)
Number of subjects: 76
Study 8380634 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin (CDDP; 80 mg/m2 on day 1) plus Mitomycin C (MMC; 8 mg/m2 on days 1 and 8)
Number of subjects: 76
Study 2427846 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol 200 mg
Number of subjects: 19
Study 2427846 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol 400 mg
Number of subjects: 19
Study 2427846 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 100 mg
Number of subjects: 19
Study 30236087 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacryocystorhinostomy with Silicone tubes and Ologen implants (Group B)
Number of subjects: 60
Study 30236087 — intervention group
Group type: COMPARATOR
Intervention: Dacryocystorhinostomy with Silicone tubes (Group A)
Number of subjects: 60
Study 28317354 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved appliance FR III
Number of subjects: 40
Study 28317354 — intervention group
Group type: COMPARATOR
Intervention: Classic appliance FR III
Number of subjects: 40
Study 23467836 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-session group
Number of subjects: 26
Study 23467836 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-session group
Number of subjects: 26
Study 22777936 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril (2-year angiotensin-converting enzyme inhibition)
Number of subjects: 397
Study 22777936 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 397
Study 22777936 — intervention group
Group type: EXPERIMENTAL
Intervention: Visit-to-visit blood pressure variability assessment
Number of subjects: 397
Study 21107100 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 230
Study 21107100 — intervention group
Group type: COMPARATOR
Intervention: Surgical resection (RES)
Number of subjects: 230
Study 18387854 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TENS
Number of subjects: 40
Study 18387854 — intervention group
Group type: COMPARATOR
Intervention: Placebo TENS
Number of subjects: 40
Study 15735611 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice 300 mL
Number of subjects: 12
Study 15735611 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice 1200 mL
Number of subjects: 12
Study 15735611 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 12
Study 12824095 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin treatment
Number of subjects: 0
Study 12824095 — intervention group
Group type: EXPERIMENTAL
Intervention: Ex‐warfarin users
Number of subjects: 0
Study 10810938 — intervention group
Group type: EXPERIMENTAL
Intervention: Acuvue
Number of subjects: 6
Study 10810938 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentle Touch
Number of subjects: 6
Study 10810938 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency 38
Number of subjects: 6
Study 10810938 — intervention group
Group type: EXPERIMENTAL
Intervention: Proclear
Number of subjects: 6
Study 8856481 — intervention group
Group type: EXPERIMENTAL
Intervention: LRB081 10 mg
Number of subjects: 8
Study 8856481 — intervention group
Group type: EXPERIMENTAL
Intervention: LRB081 40 mg
Number of subjects: 8
Study 8856481 — intervention group
Group type: EXPERIMENTAL
Intervention: LRB081 80 mg
Number of subjects: 8
Study 8856481 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 8856481 — intervention group
Group type: EXPERIMENTAL
Intervention: LRB081
Number of subjects: 8
Study 1732347 — intervention group
Group type: EXPERIMENTAL
Intervention: Urokinase (4,400 U/kg as an intravenous bolus infusion, then 4,400 U/kg per h over 12 h; n = 29)
Number of subjects: 63
Study 1732347 — intervention group
Group type: COMPARATOR
Intervention: Alteplase (10 mg as an intravenous bolus infusion, then 90 mg over 2 h; n = 34)
Number of subjects: 63
Study 1732347 — intervention group
Group type: EXPERIMENTAL
Intervention: Urokinase
Number of subjects: 63
Study 1732347 — intervention group
Group type: COMPARATOR
Intervention: Alteplase
Number of subjects: 63
Study 6374263 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol eye drops 1%
Number of subjects: 41
Study 6374263 — intervention group
Group type: COMPARATOR
Intervention: Timolol eye drops 0.5%
Number of subjects: 41
Study 29901560 — intervention group
Group type: EXPERIMENTAL
Intervention: DFCI 00-01 protocol
Number of subjects: 4
Study 29901560 — intervention group
Group type: COMPARATOR
Intervention: DFCI 95-01 protocol
Number of subjects: 4
Study 29901560 — intervention group
Group type: COMPARATOR
Intervention: High-risk patients
Number of subjects: 4
Study 26202320 — intervention group
Group type: COMPARATOR
Intervention: Text-only warnings
Number of subjects: 2083
Study 26202320 — intervention group
Group type: EXPERIMENTAL
Intervention: Graphic pictorial warnings
Number of subjects: 2083
Study 26202320 — intervention group
Group type: EXPERIMENTAL
Intervention: Symbolic pictorial warnings
Number of subjects: 2083
Study 26202320 — intervention group
Group type: EXPERIMENTAL
Intervention: Testimonial pictorial warnings
Number of subjects: 2083
Study 24269645 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 50 mg
Number of subjects: 40
Study 24269645 — intervention group
Group type: COMPARATOR
Intervention: Ketorolac 30 mg
Number of subjects: 40
Study 22242700 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified directly observed therapy (mDOT)
Number of subjects: 21
Study 22242700 — intervention group
Group type: COMPARATOR
Intervention: Self-administered therapy (SAT)
Number of subjects: 21
Study 20718911 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic performance measures
Number of subjects: 8
Study 20718911 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory performance
Number of subjects: 8
Study 20718911 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis
Number of subjects: 8
Study 19101390 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple courses of antenatal corticosteroids (n=937)
Number of subjects: 1858
Study 19101390 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=921)
Number of subjects: 1858
Study 15638890 — intervention group
Group type: EXPERIMENTAL
Intervention: T2N0M0 group (n=21)
Number of subjects: 118
Study 15638890 — intervention group
Group type: EXPERIMENTAL
Intervention: T3aN0M0 group (n=97)
Number of subjects: 118
Study 12416659 — intervention group
Group type: EXPERIMENTAL
Intervention: IBI/S (silybin-beta-cyclodextrin) 135 mg/d
Number of subjects: 60
Study 12416659 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 9682116 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacoemulsification (Group 1)
Number of subjects: 60
Study 9682116 — intervention group
Group type: EXPERIMENTAL
Intervention: ECCE with continuous curvilinear capsulorhexis (Group 2)
Number of subjects: 60
Study 9682116 — intervention group
Group type: EXPERIMENTAL
Intervention: ECCE with letter‐box capsulotomy (Group 3)
Number of subjects: 60
Study 8595515 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple combination therapy
Number of subjects: 0
Study 8595515 — intervention group
Group type: COMPARATOR
Intervention: Double combination therapy
Number of subjects: 0
Study 8595515 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy
Number of subjects: 0
Study 2576261 — intervention group
Group type: EXPERIMENTAL
Intervention: OC containing 75 micrograms gestodene (GTD) and 30 micrograms ethinyl estradiol (EE)
Number of subjects: 49
Study 2576261 — intervention group
Group type: EXPERIMENTAL
Intervention: OC with 150 micrograms desogestrel (DSG) and 30 micrograms EE
Number of subjects: 49
Study 792404 — intervention group
Group type: EXPERIMENTAL
Intervention: Estolate suspension
Number of subjects: 0
Study 792404 — intervention group
Group type: COMPARATOR
Intervention: Ethyl succinate suspension
Number of subjects: 0
Study 31430545 — intervention group
Group type: EXPERIMENTAL
Intervention: Breath awareness meditation
Number of subjects: 1
Study 31430545 — intervention group
Group type: COMPARATOR
Intervention: Active control task
Number of subjects: 1
Study 28557589 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroimplantation technique
Number of subjects: 102
Study 28557589 — intervention group
Group type: COMPARATOR
Intervention: Ophthalmic viscosurgical device
Number of subjects: 102
Study 28557589 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 102
Study 26391621 — intervention group
Group type: EXPERIMENTAL
Intervention: Cogmed working memory program (intervention group)
Number of subjects: 77
Study 26391621 — intervention group
Group type: COMPARATOR
Intervention: Waitlist-control (control group)
Number of subjects: 77
Study 23352760 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine treatment (10 μg/kg/h during the neonatal period)
Number of subjects: 0
Study 21070193 — intervention group
Group type: EXPERIMENTAL
Intervention: Assertive Community Treatment (ACT)
Number of subjects: 118
Study 21070193 — intervention group
Group type: COMPARATOR
Intervention: Usual hospital-based rehabilitation program (Control)
Number of subjects: 118
Study 19736510 — intervention group
Group type: EXPERIMENTAL
Intervention: EC‐‐>DOC (4x epirubicin/cyclophosphamide; 4x docetaxel)
Number of subjects: 110
Study 19736510 — intervention group
Group type: COMPARATOR
Intervention: CMF (Cyclophosphamide, Methotrexate, Fluorouracil)
Number of subjects: 110
Study 16682304 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 168
Study 16682304 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study 10398579 — intervention group
Group type: EXPERIMENTAL
Intervention: ThinPrep preparations
Number of subjects: 473
Study 10398579 — intervention group
Group type: COMPARATOR
Intervention: Conventional Pap smears
Number of subjects: 473
Study 8656444 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy plus tamoxifen (n = 38)
Number of subjects: 196
Study 8656444 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone (n = 46)
Number of subjects: 196
Study 8656444 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen with radiotherapy
Number of subjects: 196
Study 8656444 — intervention group
Group type: EXPERIMENTAL
Intervention: Total radiation dose
Number of subjects: 196
Study 1854047 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopentone (4 mg.kg‐1)
Number of subjects: 16
Study 1854047 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate (0.5 mg.kg‐1)
Number of subjects: 16
Study 1854047 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Thiopentone and Etomidate)
Number of subjects: 16
Study 6217961 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous blind liver biopsy (PB)
Number of subjects: 126
Study 6217961 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopy with guided biopsy (LB)
Number of subjects: 126
Study 31701432 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour recall with reminders
Number of subjects: 2400
Study 31701432 — intervention group
Group type: COMPARATOR
Intervention: No recall period (standard PROMIS administration)
Number of subjects: 2400
Study 31701432 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day recall
Number of subjects: 2400
Study 31701432 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour recall
Number of subjects: 2400
Study 29181852 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch (HES)
Number of subjects: 5
Study 29181852 — intervention group
Group type: COMPARATOR
Intervention: Eleview®
Number of subjects: 5
Study 28965380 — intervention group
Group type: EXPERIMENTAL
Intervention: Inlaid labial mucosal graft repair (LMGR)
Number of subjects: 55
Study 28965380 — intervention group
Group type: COMPARATOR
Intervention: Bladder mucosal graft repair (BMGR)
Number of subjects: 55
Study 24225449 — intervention group
Group type: EXPERIMENTAL
Intervention: SFA-rich diet (18% energy)
Number of subjects: 24
Study 24225449 — intervention group
Group type: EXPERIMENTAL
Intervention: n-6 PUFA-rich diet (10% energy)
Number of subjects: 24
Study 24225449 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific control diet mentioned)
Number of subjects: 24
Study 22236931 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline for 8 weeks
Number of subjects: 272
Study 22236931 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patches
Number of subjects: 272
Study 22236931 — intervention group
Group type: COMPARATOR
Intervention: Brief counselling (Control Group 1)
Number of subjects: 272
Study 20609435 — intervention group
Group type: EXPERIMENTAL
Intervention: EX/RP+MI
Number of subjects: 30
Study 20609435 — intervention group
Group type: COMPARATOR
Intervention: EX/RP
Number of subjects: 30
Study 17906192 — intervention group
Group type: EXPERIMENTAL
Intervention: EGCG (300 mg/d for 2 days)
Number of subjects: 6
Study 17906192 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 16140426 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 cans/day of a protein and energy dense oral nutrition supplement +/− n-3 fatty acids
Number of subjects: 200
Study 16140426 — intervention group
Group type: COMPARATOR
Intervention: Noncompliant patients (less than 1.5 cans/day)
Number of subjects: 200
Study 16140426 — intervention group
Group type: EXPERIMENTAL
Intervention: Compliant patients (1.5 cans/day or more)
Number of subjects: 200
Study 12153743 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 16
Study 12153743 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 10440564 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-faceted intervention including six components: (1) mailing of six practice recommendations in a CME course; (2) mailing of supplementary practice-based tools; (3) follow-up mailings reinforcing recommendations; (4) invitation to an AAN-sponsored seminar; (5) endorsement by opinion leaders; (6) specialty-society sponsorship and endorsement.
Number of subjects: 417
Study 10440564 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 417
Study 10440564 — intervention group
Group type: COMPARATOR
Intervention: Baseline group (not specified in detail).
Number of subjects: 417
Study 10440564 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-faceted intervention.
Number of subjects: 417
Study 7751491 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended Relationship Enhancement (ERE)
Number of subjects: 188
Study 7751491 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Broad‐spectrum (BBS)
Number of subjects: 188
Study 7751491 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended Cognitive‐Behavioral (ECB)
Number of subjects: 188
Study 2138489 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxacurium (initial dose of 25 micrograms kg‐1, with incremental doses of 5 micrograms kg‐1)
Number of subjects: 35
Study 2138489 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine (0.08 mg kg‐1)
Number of subjects: 35
Study 2138489 — intervention group
Group type: EXPERIMENTAL
Intervention: Edrophonium (1.0 mg kg‐1)
Number of subjects: 35
Study 28746243 — intervention group
Group type: EXPERIMENTAL
Intervention: Barbell hip thrust strength training (n = 11)
Number of subjects: 21
Study 28746243 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 10)
Number of subjects: 21
Study 30082073 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine 10 mg daily
Number of subjects: 2298
Study 30082073 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine 20 mg daily
Number of subjects: 2298
Study 30082073 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2298
Study 26730716 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline (2 mg/day)
Number of subjects: 87
Study 24885673 — intervention group
Group type: EXPERIMENTAL
Intervention: Dader Method of pharmaceutical care
Number of subjects: 0
Study 24885673 — intervention group
Group type: COMPARATOR
Intervention: Usual care and verbal-written counseling regarding BD
Number of subjects: 0
Study 22273548 — intervention group
Group type: EXPERIMENTAL
Intervention: Threatening information regarding the heat stimulus
Number of subjects: 56
Study 22273548 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of parental catastrophizing
Number of subjects: 56
Study 22273548 — intervention group
Group type: COMPARATOR
Intervention: Neutral information regarding the heat stimulus
Number of subjects: 56
Study 21418281 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 3% diclofenac sodium plus hyaluronan (DFS) gel, twice daily for 12 weeks
Number of subjects: 61
Study 21418281 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 5% imiquimod (IMQ) cream, twice per week for 16 weeks
Number of subjects: 61
Study 21418281 — intervention group
Group type: COMPARATOR
Intervention: Base cream (BC), twice daily for 12 weeks
Number of subjects: 61
Study 16810714 — intervention group
Group type: EXPERIMENTAL
Intervention: Wald test with intra-subject variability
Number of subjects: 12
Study 16810714 — intervention group
Group type: EXPERIMENTAL
Intervention: LRT with intra-subject variability
Number of subjects: 12
Study 16810714 — intervention group
Group type: EXPERIMENTAL
Intervention: Wald test for bioequivalence trials
Number of subjects: 12
Study 16810714 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir treatment
Number of subjects: 12
Study 15643103 — intervention group
Group type: EXPERIMENTAL
Intervention: Gepirone ER (20 mg/d titrated to 40 to 80 mg/d)
Number of subjects: 420
Study 15643103 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 420
Study 15643103 — intervention group
Group type: EXPERIMENTAL
Intervention: Gepirone ER
Number of subjects: 420
Study 12224305 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunosuppressive agents
Number of subjects: 66
Study 12224305 — intervention group
Group type: EXPERIMENTAL
Intervention: 99Tc-MDP
Number of subjects: 66
Study 12224305 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunosuppressive agents and 99Tc-MDP
Number of subjects: 66
Study 10428516 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracutaneous injections of 0.1 mL sterile water
Number of subjects: 99
Study 10428516 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous injections of 0.5 mL sterile water
Number of subjects: 99
Study 10428516 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 99
Study 7763029 — intervention group
Group type: EXPERIMENTAL
Intervention: FEC regimen (Epirubicin, Fluorouracil, Cyclophosphamide)
Number of subjects: 158
Study 7763029 — intervention group
Group type: COMPARATOR
Intervention: FNC regimen (Mitoxantrone, Fluorouracil, Cyclophosphamide)
Number of subjects: 158
Study 7763029 — intervention group
Group type: EXPERIMENTAL
Intervention: FEC regimen
Number of subjects: 158
Study 7763029 — intervention group
Group type: COMPARATOR
Intervention: FNC regimen
Number of subjects: 158
Study 1969982 — intervention group
Group type: EXPERIMENTAL
Intervention: CGRP infusion at progressively increased concentrations
Number of subjects: 15
Study 1969982 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 15
Study 393571 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal gastric vagotomy
Number of subjects: 20
Study 393571 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzilonium (anticholinergic, 70 micrograms/kg)
Number of subjects: 20
Study 393571 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (30 micrograms/kg)
Number of subjects: 20
Study 393571 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (50 micrograms/kg)
Number of subjects: 20
Study 393571 — intervention group
Group type: COMPARATOR
Intervention: Sham feeding
Number of subjects: 20
Study 31805973 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Go NAPSACC
Number of subjects: 485
Study 31805973 — intervention group
Group type: COMPARATOR
Intervention: Basic Go NAPSACC
Number of subjects: 485
Study 28775942 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician's advice with standard counselling
Number of subjects: 160
Study 28775942 — intervention group
Group type: COMPARATOR
Intervention: Standard counselling alone
Number of subjects: 160
Study 25850390 — intervention group
Group type: EXPERIMENTAL
Intervention: Zero-P spacer (group A)
Number of subjects: 69
Study 25850390 — intervention group
Group type: COMPARATOR
Intervention: Anterior cervical plate and interbody cage (group B)
Number of subjects: 69
Study 23298192 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-phytate pea diet (30% inclusion, 0.45% available phosphorus)
Number of subjects: 180
Study 23298192 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-phytate pea diet (30% inclusion, 0.3% available phosphorus)
Number of subjects: 180
Study 23298192 — intervention group
Group type: EXPERIMENTAL
Intervention: Low phosphorus diet (0.3% available phosphorus)
Number of subjects: 180
Study 23298192 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-phytate pea diet
Number of subjects: 180
Study 23298192 — intervention group
Group type: COMPARATOR
Intervention: Normal pea diet
Number of subjects: 180
Study 23298192 — intervention group
Group type: COMPARATOR
Intervention: Soybean meal diet
Number of subjects: 180
Study 20659260 — intervention group
Group type: EXPERIMENTAL
Intervention: SB12® (0.025% chlorhexidine and 0.3% zinc)
Number of subjects: 0
Study 20659260 — intervention group
Group type: EXPERIMENTAL
Intervention: Listerine®
Number of subjects: 0
Study 20659260 — intervention group
Group type: EXPERIMENTAL
Intervention: BreathRx®
Number of subjects: 0
Study 20659260 — intervention group
Group type: EXPERIMENTAL
Intervention: SmartMouth®
Number of subjects: 0
Study 20659260 — intervention group
Group type: EXPERIMENTAL
Intervention: LacerFresh®
Number of subjects: 0
Study 20659260 — intervention group
Group type: COMPARATOR
Intervention: Water (negative control)
Number of subjects: 0
Study 19075055 — intervention group
Group type: EXPERIMENTAL
Intervention: aplaviroc plus lamivudine-zidovudine (Combivir)
Number of subjects: 8
Study 17321923 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia with 10 mg of hyperbaric 1% lidocaine (L group, n=40)
Number of subjects: 80